IRONWOOD PHARMACEUTICALS INC Contracts & Agreements

Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024 (Filed With SEC on February 16, 2024)

Form of Restricted Stock Unit Agreement under the Amended and Restated 2019 Equity Incentive Plan (Filed With SEC on November 9, 2023)

Amended and Restated 2019 Equity Incentive Plan (Filed With SEC on June 22, 2023)

Transaction Agreement, dated May 21, 2023, by and between Ironwood Pharmaceuticals, Inc. and VectivBio Holding AG (Filed With SEC on May 22, 2023)

Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023 (Filed With SEC on February 16, 2023)

Form of Executive Severance Agreement (Filed With SEC on December 1, 2021)

Second Amended and Restated Executive Severance Agreement, dated June 22, 2021, between Ironwood Pharmaceuticals, Inc. and Thomas McCourt (Filed With SEC on June 24, 2021)

Description of Securities of Ironwood Pharmaceuticals, Inc (Filed With SEC on February 17, 2021)

Amendment to the Amended and Restated License Agreement, dated as of January 8, 2021, by and between Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc (Filed With SEC on February 17, 2021)

Form of Performance-Based Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan (Filed With SEC on May 6, 2020)

Amended and Restated Executive Severance Agreement, February 26, 2019, between Ironwood Pharmaceuticals, Inc. and Halley Gilbert (Filed With SEC on May 6, 2020)

Separation Agreement, dated as revised February 18, 2020, between Ironwood Pharmaceuticals, Inc. and Halley Gilbert (Filed With SEC on May 6, 2020)

Services Agreement, February 29, 2020, between Ironwood Pharmaceuticals, Inc. and Halley Gilbert (Filed With SEC on May 6, 2020)

Amended and Restated License and Collaboration Agreement, dated as of September 16, 2019, by and between AstraZeneca AB and Ironwood Pharmaceuticals, Inc (Filed With SEC on September 18, 2019)

Purchase Agreement, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and J.P. Morgan Securities LLC (Filed With SEC on August 13, 2019)

Base Call Option Transaction Confirmation for the 2024 Notes, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association (Filed With SEC on August 13, 2019)

Base Call Option Transaction Confirmation for the 2026 Notes, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association (Filed With SEC on August 13, 2019)

Base Call Option Transaction Confirmation for the 2024 Notes, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and Credit Suisse Capital LLC (Filed With SEC on August 13, 2019)

Base Call Option Transaction Confirmation, for the 2026 Notes, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and Credit Suisse Capital LLC (Filed With SEC on August 13, 2019)

Additional Call Option Transaction Confirmation for the 2024 Notes, dated as of August 12, 2019, between Ironwood Pharmaceuticals, Inc. and JPMorgan Chase Bank, National... (Filed With SEC on August 13, 2019)

Additional Call Option Transaction Confirmation for the 2026 Notes, dated as of August 12, 2019, between Ironwood Pharmaceuticals, Inc. and JPMorgan Chase Bank, National... (Filed With SEC on August 13, 2019)

Additional Call Option Transaction Confirmation for the 2024 Notes, dated as of August 12, 2019, between Ironwood Pharmaceuticals, Inc. and Credit Suisse Capital LLC (Filed With SEC on August 13, 2019)

Additional Call Option Transaction Confirmation for the 2026 Notes, dated as of August 12, 2019, between Ironwood Pharmaceuticals, Inc. and Credit Suisse Capital LLC (Filed With SEC on August 13, 2019)

Call Spread Unwind Agreement, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association (Filed With SEC on August 13, 2019)

Call Spread Unwind Agreement, dated as of August 7, 2019, between Ironwood Pharmaceuticals, Inc. and Credit Suisse Capital LLC (Filed With SEC on August 13, 2019)

Indenture, dated as of August 12, 2019, by and between Ironwood Pharmaceuticals, Inc. and U.S. Bank National Association (including the form of the 0.75% Convertible Senior Note... (Filed With SEC on August 13, 2019)

Indenture, dated as of August 12, 2019, by and between Ironwood Pharmaceuticals, Inc. and U.S. Bank National Association (including the form of the 1.50% Convertible Senior Note... (Filed With SEC on August 13, 2019)

Amended and Restated License Agreement, dated as of August 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc (Filed With SEC on August 1, 2019)

2019 Equity Incentive Plan (Filed With SEC on July 30, 2019)

Form of Non-statutory Stock Option Agreement under the 2019 Equity Incentive Plan (Filed With SEC on July 30, 2019)

Form of Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan (Filed With SEC on July 30, 2019)

Form of Restricted Stock Agreement under the 2019 Equity Incentive Plan (Filed With SEC on July 30, 2019)

Non-employee Director Compensation Policy, effective May 20, 2019 (Filed With SEC on July 30, 2019)

Form of Non-Employee Director Restricted Stock Award Agreement under the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on July 30, 2019)

Lease Agreement for facilities at 100 Summer Street, Boston, Massachusetts, dated as of June 11, 2019, by and between Ironwood Pharmaceuticals, Inc. and MA-100 Summer Street... (Filed With SEC on June 13, 2019)

Lease Termination Agreement for facilities at 301 Binney Street, Cambridge, Massachusetts, dated as of June 11, 2019, by and between Ironwood Pharmaceuticals, Inc. and BMR-Rogers... (Filed With SEC on June 13, 2019)

2019 Equity Incentive Plan (Filed With SEC on May 31, 2019)

Supplemental Indenture dated as of April 5, 2019 by and between Ironwood Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on April 8, 2019)

Tax Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 4, 2019)

Employee Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 4, 2019)

Thirteenth Amendment to Lease, dated as of April 1, 2019, by and between BMR-Rogers Street LLC and Ironwood Pharmaceuticals, Inc (Filed With SEC on April 4, 2019)

Separation Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 4, 2019)

Form of Executive Severance Agreement (Filed With SEC on February 25, 2019)

Offer Letter, dated January 3, 2019, between Ironwood Pharmaceuticals, Inc. and Mark Mallon (Filed With SEC on January 4, 2019)

Form of Stock Option Agreement under the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on November 6, 2018)

Form of Restricted Stock Unit Agreement under the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on November 6, 2018)

Form of Executive Severance Agreement (Filed With SEC on November 6, 2018)

AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on May 8, 2017)

COMMERCIAL AGREEMENT BY AND AMONG ALLERGAN USA, INC., Ironwood Pharmaceuticals, Inc. AND Forest Laboratories, LLC DATED AS OF JANUARY 31, 2017 (Filed With SEC on May 8, 2017)

TWELFTH AMENDMENT TO LEASE (Filed With SEC on May 8, 2017)

ELEVENTH AMENDMENT TO LEASE (Filed With SEC on February 22, 2017)

LICENSE AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and ARDEA BIOSCIENCES, INC. April 26, 2016 (Filed With SEC on August 8, 2016)

APRIL 26, 2016 AstraZeneca Pharmaceuticals LP -and- Ironwood Pharmaceuticals, Inc. COMMERCIAL SUPPLY AGREEMENT Zurampic Product and Allopurinol Combination Product (Filed With SEC on August 8, 2016)

AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on February 19, 2016)

DATE: OCTOBER 26, 2015 (Filed With SEC on February 19, 2016)

IRONWOOD PHARMACEUTICALS, INC. 2.25% Convertible Senior Notes due 2022 Purchase Agreement (Filed With SEC on June 15, 2015)

IRONWOOD PHARMACEUTICALS, INC. 2.25% CONVERTIBLE SENIOR NOTES DUE 2022 INDENTURE DATED AS OF JUNE 15, 2015 U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE (Filed With SEC on June 15, 2015)

HEALTHCARE PROVIDER CONSULTING AGREEMENT (Filed With SEC on May 6, 2015)

IRONWOOD PHARMACEUTICALS, INC. Stock Option Grant Notice Stock Option Grant under the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on February 18, 2015)

RESTRICTED STOCK AGREEMENT IRONWOOD PHARMACEUTICALS, INC. (Filed With SEC on February 18, 2015)

IRONWOOD PHARMACEUTICALS, INC. Restricted Stock Unit Award Notice Restricted Stock Unit Award under the Amended and Restated 2010 Employee, Director and Consultant Equity... (Filed With SEC on February 18, 2015)

IRONWOOD PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AGREEMENT (Filed With SEC on February 18, 2015)

HEALTHCARE PROVIDER CONSULTING AGREEMENT Ironwood Contract #HIP-541 (Filed With SEC on February 18, 2015)

EIGHTH AMENDMENT TO LEASE (Filed With SEC on February 18, 2015)

NINTH AMENDMENT TO LEASE (Filed With SEC on February 18, 2015)

TENTH AMENDMENT TO LEASE (Filed With SEC on February 18, 2015)

SUBLEASE (Filed With SEC on February 18, 2015)

IRONWOOD PHARMACEUTICALS, INC. CHANGE OF CONTROL SEVERANCE BENEFIT PLAN Adopted on May 5, 2009 Amended and Restated on April 26, 2014 (Filed With SEC on April 29, 2014)

IRONWOOD PHARMACEUTICALS, INC. 13,725,500 Shares of Class A common stock Underwriting Agreement (Filed With SEC on February 12, 2014)

RESTRICTED STOCK AGREEMENT IRONWOOD PHARMACEUTICALS, INC. (Filed With SEC on February 7, 2014)

DIRECTOR COMPENSATION PLAN (Filed With SEC on February 7, 2014)

THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT (Filed With SEC on February 7, 2014)

AMENDMENT (Filed With SEC on August 8, 2013)

IRONWOOD PHARMACEUTICALS, INC. 10,500,000 Shares of Class A common stock Underwriting Agreement (Filed With SEC on May 24, 2013)

IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on February 21, 2013)

IRONWOOD PHARMACEUTICALS, INC. CHANGE OF CONTROL SEVERANCE BENEFIT PLAN Adopted on May 5, 2009 Amended and Restated on July 30, 2012 (Filed With SEC on February 21, 2013)

AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (Filed With SEC on February 21, 2013)

COLLABORATION AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and ASTRAZENECA AB October 23, 2012 (Filed With SEC on February 21, 2013)

SIXTH AMENDMENT TO LEASE (Filed With SEC on February 21, 2013)

SEVENTH AMENDMENT TO LEASE (Filed With SEC on February 21, 2013)

INDENTURE dated as of January 4, 2013 by and between IRONWOOD PHARMACEUTICALS, INC., a Delaware corporation, as issuer of the Notes described herein, and U.S. BANK NATIONAL... (Filed With SEC on January 8, 2013)

FIFTH AMENDMENT TO LEASE (Filed With SEC on February 29, 2012)

IRONWOOD PHARMACEUTICALS, INC. 5,250,000 Shares of Class A common stock Underwriting Agreement (Filed With SEC on February 15, 2012)

IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2010 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Filed With SEC on May 13, 2011)

COMMERCIAL SUPPLY AGREEMENT (Filed With SEC on May 13, 2011)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 30, 2011)

FOURTH AMENDMENT TO LEASE (Filed With SEC on March 30, 2011)

COMMERCIALSUPPLY AGREEMENT regarding Linaclotide(MD-1100) among PolyPeptideLaboratories, Inc. 365 Maple Ave, Torrance CA 90503 and PolyPeptideLaboratories (SWEDEN) AB PO Box 30089... (Filed With SEC on August 10, 2010)

IRONWOOD PHARMACEUTICALS, INC. Stock Option Grant Notice Stock Option Grant under the Companys 2010 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on March 30, 2010)

SECOND AMENDMENT TO LEASE (Filed With SEC on March 30, 2010)

COLLABORATIONAGREEMENT byand between MICROBIA,INC. and FORESTLABORATORIES, INC. SEPTEMBER 12, 2007 (Filed With SEC on February 2, 2010)

LICENSE AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and LABORATORIOS ALMIRALL, S.A. April 30, 2009 (Filed With SEC on February 2, 2010)

LICENSE AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and ASTELLAS PHARMA INC. November 10, 2009 (Filed With SEC on February 2, 2010)

IRONWOOD PHARMACEUTICALS,INC. Shares of Series ACommon Stock Underwriting Agreement (Filed With SEC on January 29, 2010)

IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (Filed With SEC on January 29, 2010)

IRONWOOD PHARMACEUTICALS,INC. Shares of Series ACommon Stock Underwriting Agreement (Filed With SEC on January 20, 2010)

Shares (Filed With SEC on January 20, 2010)

IRONWOODPHARMACEUTICALS, INC. 2010EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Filed With SEC on January 20, 2010)

IRONWOOD PHARMACEUTICALS, INC. 2010 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on January 20, 2010)

MICROBIA,INC. 1998AMENDED AND RESTATED STOCK OPTION PLAN Adoptedby Board of Directors on July 10, 1998 Amendedby Board of Directors on December 21, 1999 Approvedas Amended By... (Filed With SEC on December 23, 2009)

IRONWOOD PHARMACEUTICALS, INC. AMENDED ANDRESTATED 2002 STOCK INCENTIVE PLAN (Filed With SEC on December 23, 2009)

IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (Filed With SEC on December 23, 2009)

IRONWOODPHARMACEUTICALS, INC. (Filed With SEC on December 23, 2009)

DIRECTOR COMPENSATION (Filed With SEC on December 23, 2009)

CONSULTING AGREEMENT Contract # CNSLT-3775 (Filed With SEC on December 23, 2009)

COLLABORATION AGREEMENT by and between MICROBIA, INC. and FOREST LABORATORIES, INC. September12, 2007 (Filed With SEC on December 23, 2009)

LICENSE AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and LABORATORIOS ALMIRALL, S.A. April 30, 2009 (Filed With SEC on December 23, 2009)

LICENSE AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and ASTELLAS PHARMA INC. November 10, 2009 (Filed With SEC on December 23, 2009)

INDEMNIFICATIONAGREEMENT (Filed With SEC on December 23, 2009)

MICROBIA, INC. TERMS OF AMENDED AND RESTATED LEASE 320 BENT STREET, CAMBRIDGE, MA TABLE OF CONTENTS (Filed With SEC on December 23, 2009)

MICROBIA, INC. 301 BINNEY STREET CAMBRIDGE, MA TABLE OF CONTENTS (Filed With SEC on December 23, 2009)

MASTER SECURITY AGREEMENT No. 8081150 Dated as of January 16, 2009 (Agreement) (Filed With SEC on December 23, 2009)

EIGHTHAMENDED AND RESTATED INVESTORSRIGHTS AGREEMENT BY ANDAMONG IRONWOODPHARMACEUTICALS, INC., THEFOUNDERS AND THEINVESTORS NAMED IN EXHIBIT A September 1,2009 (Filed With SEC on November 20, 2009)

Category

Industry

Companies

Contracts

IRONWOOD PHARMACEUTICALS INC Contracts & Agreements